TaiheCap

TaiheCap (泰珑/泰鲲资本) is a healthcare-focused investment fund that led the over-RMB-100-million Series B1 round for iPSC-derived neural cell drug developer Shize Biotech in late 2024 or early 2025, with co-investors Qisheng Capital and Tianhui Capital joining and existing shareholders including FreeS Capital, Qiming Venture Partners, Lilly Asia Ventures, and Sequoia China adding to their stakes . The fund also appears as a participant in broader biotech financing, having co-invested alongside Tianhui Capital in Biointron's nearly RMB 500 million Series B round in 2022 . elsewheres corpus does not contain further detail on the fund's vintage, AUM, or full portfolio.